Biotechnology
Technology
Health

Vericel

$18.18
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.15 (-5.95%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Vericel and other stocks, options, ETFs, and crypto commission-free!

About

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies to repair and regenerate damaged tissues and organs to normal structure and function. Its product portfolio includes MACI and Epicel. Read More The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns comprising a total body surface area of greater than or equal to 30%. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.

Employees
216
Headquarters
Cambridge, Massachusetts
Founded
1989
Market Cap
842.36M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
977.28K
High Today
$19.19
Low Today
$18.09
Open Price
$19.17
Volume
192.72K
52 Week High
$21.01
52 Week Low
$8.95

Collections

Biotechnology
Technology
Health
Medical
Engineering
2014 IPO
US
North America

News

Seeking AlphaMar 20

Osiris Therapeutics: Elucidating The Ramifications Of The Latest Buyout

I also share my insight on the potential buyout of Vericel and BioLife Solutions, as well as other candidates for 2019. In the long run, it's not just how much money you make that will determine your future prosperity. It's how much of that money you put to work by saving it and investing it. - Peter Lynch (stellar value and growth investor) On March 12, 2019, Osiris Therapeutics (OSIR) disclosed that Smith & Nephew (SNN) agreed to acquire the company for $660 million. At this price, the buyout equates...

12
Seeking AlphaMar 18

Vericel's Q4 Swoon: The Fainting Spell Is Temporary

Management's mention of ReCell complicates the Epicel picture; is it a competitor, an acquisition target, or a non-factor? (Or, perhaps all three?). The earnings day price swoon was a result of disappointing guidance and a clouding of the Epicel picture. But, should we be worried? In a word: no. We knew it had to end sometime. After four outstanding earnings day moves, including three gap-ups and third quarter 2018's spectacular +44% price explosion, on February 26, 2019, Vericel (VCEL) released its usual...

0
MarketBeatMar 7

Stock Price, News, & Analysis for Vericel

Media headlines about VCEL stock have trended neutral recently, InfoTrie reports. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Vericel earned a coverage optimism score of 0.3 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of ...

23

Earnings

-$0.21
-$0.10
$0.00
$0.11
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 8, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.